These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 12356807)

  • 21. Salicylate induction of phenotypic resistance to quinolones in Serratia marcescens.
    Berlanga M; Viñas M
    J Antimicrob Chemother; 2000 Aug; 46(2):279-82. PubMed ID: 10933653
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Virulence factors and resistance mechanisms of Serratia marcescens. A short review.
    Rodrigues AP; Holanda AR; Lustosa GP; Nóbrega SM; Santana WJ; Souza LB; Coutinho HD
    Acta Microbiol Immunol Hung; 2006 Mar; 53(1):89-93. PubMed ID: 16696552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro emergence of quinolone-resistant mutants of Escherichia coli, Enterobacter cloacae, and Serratia marcescens.
    Watanabe M; Kotera Y; Yosue K; Inoue M; Mitsuhashi S
    Antimicrob Agents Chemother; 1990 Jan; 34(1):173-5. PubMed ID: 2183709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
    Louie A; Brown DL; Liu W; Kulawy RW; Deziel MR; Drusano GL
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3988-4000. PubMed ID: 17846144
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Efflux systems in Serratia marcescens].
    Mardanova AM; Bogomol'naia LM; Romanova IuD; Sharipova MR
    Mikrobiologiia; 2014; 83(1):3-14. PubMed ID: 25423729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibiotic susceptibility of Serratia marcescens and Serratia liquefaciens.
    Traub WH
    Chemotherapy; 2000; 46(5):315-21. PubMed ID: 10965096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of subinhibitory levels of aminoglycosides and fluoroquinolines on hydrophobicity and motility of Serratia marcescens].
    Majtán V; Majtánová L
    Epidemiol Mikrobiol Imunol; 2001 Feb; 50(1):26-30. PubMed ID: 11233670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional gene cloning and characterization of the SsmE multidrug efflux pump from Serratia marcescens.
    Minato Y; Shahcheraghi F; Ogawa W; Kuroda T; Tsuchiya T
    Biol Pharm Bull; 2008 Mar; 31(3):516-9. PubMed ID: 18310921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
    Gilbert DN; Kohlhepp SJ; Slama KA; Grunkemeier G; Lewis G; Dworkin RJ; Slaughter SE; Leggett JE
    Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incomplete cross-resistance of nalidixic and pipemidic acid-resistant variants of Serratia marcescens against ciprofloxacin, enoxacin, and norfloxacin.
    Traub WH
    Chemotherapy; 1985; 31(1):34-9. PubMed ID: 3156026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy.
    Lomovskaya O; Warren MS; Lee A; Galazzo J; Fronko R; Lee M; Blais J; Cho D; Chamberland S; Renau T; Leger R; Hecker S; Watkins W; Hoshino K; Ishida H; Lee VJ
    Antimicrob Agents Chemother; 2001 Jan; 45(1):105-16. PubMed ID: 11120952
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates.
    Morgan-Linnell SK; Becnel Boyd L; Steffen D; Zechiedrich L
    Antimicrob Agents Chemother; 2009 Jan; 53(1):235-41. PubMed ID: 18838592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quinolone resistance in clinical isolates of Serratia marcescens.
    Fujimaki K; Fujii T; Aoyama H; Sato K; Inoue Y; Inoue M; Mitsuhashi S
    Antimicrob Agents Chemother; 1989 May; 33(5):785-7. PubMed ID: 2546493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence of active efflux in resistance to ciprofloxacin and to ethidium bromide by Mycoplasma hominis.
    Raherison S; Gonzalez P; Renaudin H; Charron A; Bébéar C; Bébéar CM
    Antimicrob Agents Chemother; 2002 Mar; 46(3):672-9. PubMed ID: 11850247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of the outer membrane for quinolone resistance in enterobacteria.
    Dechène M; Leying H; Cullmann W
    Chemotherapy; 1990; 36(1):13-23. PubMed ID: 2106416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of older and newer fluoroquinolones against efflux-mediated high-level ciprofloxacin-resistant Streptococcus pneumoniae.
    Daporta MT; Muñoz Bellido JL; Guirao GY; Hernández MS; García-Rodríguez JA
    Int J Antimicrob Agents; 2004 Aug; 24(2):185-7. PubMed ID: 15288320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates.
    Becnel Boyd L; Maynard MJ; Morgan-Linnell SK; Horton LB; Sucgang R; Hamill RJ; Jimenez JR; Versalovic J; Steffen D; Zechiedrich L
    Antimicrob Agents Chemother; 2009 Jan; 53(1):229-34. PubMed ID: 18838594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of Serratia marcescens porins in antibiotic resistance.
    Ruiz N; Montero T; Hernandez-Borrell J; Viñas M
    Microb Drug Resist; 2003; 9(3):257-64. PubMed ID: 12959404
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of efflux-mediated ciprofloxacin and levofloxacin resistance in recent clinical isolates of Pseudomonas aeruginosa and its reversal by the efflux pump inhibitors 1-(1-naphthylmethyl)-piperazine and phenylalanine-arginine-β-naphthylamide.
    Sonnet P; Izard D; Mullié C
    Int J Antimicrob Agents; 2012 Jan; 39(1):77-80. PubMed ID: 21974858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa.
    Pasquali F; Manfreda G
    Vet Microbiol; 2007 Jan; 119(2-4):304-10. PubMed ID: 16987619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.